 WATERTOWN, Mass., July 27, 2022 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial results on August 9, 2022 and will host a conference call at 8:30 a.m. ET that day. 